Modular Medical has crossed from development into commercial life, and the equity now prices a launch that still has not produced a reported sale. In April the Food and Drug Administration cleared Pivot, a removable two-part tubeless insulin patch pump aimed at adults who stay on multiple daily injections because existing pumps feel complex, bulky, or expensive. Initial shipments began in June, and management describes the moment as the shift from a development-stage company to a revenue-generating commercial business. The market capitalization sits near $18 million, which is less an endorsement of that claim than a wager on whether paid patients arrive before the cash is gone.
The tension is that clearance and first kits do not yet appear as revenue. The fiscal first quarter still carried no product sales against operating expenses of about $6.5 million, and cash fell to $3.9 million by quarter-end even after a registered-direct raise. Selling costs rose as research spending was cut, which is the mix of a company trying to commercialize on a shrinking cash pile. Shareholders should treat the June shipment announcement as a regulatory and operational milestone, not as proof that injection users are converting at a rate that funds the business.
After the quarter closed, an at-the-market program sold more than two million shares for about $5 million of net proceeds, lifting the share count above eight million by mid-August. That is how a going-concern issuer funds a launch when payors have not yet written checks. A national pharmacy-benefit-manager contract in early September opens a reimbursement door, but the door is not the same thing as filled prescriptions. The next several quarters resolve whether Pivot becomes a paid product or remains a cleared device financed by dilution.